[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,385,967
  • Shares Outstanding, K 33,786
  • Annual Sales, $ 55,230 K
  • Annual Income, $ -164,080 K
  • EBIT $ -135 M
  • EBITDA $ -134 M
  • 60-Month Beta 1.24
  • Price/Sales 45.47
  • Price/Cash Flow N/A
  • Price/Book 4.35

Options Overview Details

View History
  • Implied Volatility 60.24% (+7.48%)
  • Historical Volatility 64.83%
  • IV Percentile 3%
  • IV Rank 1.48%
  • IV High 558.45% on 06/05/25
  • IV Low 52.76% on 05/15/26
  • Expected Move (DTE 31) 8.16 (11.96%)
  • Put/Call Vol Ratio 0.43
  • Today's Volume 586
  • Volume Avg (30-Day) 3,624
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 28,932
  • Open Int (30-Day) 44,704
  • Expected Range 60.05 to 76.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-2.11
  • Number of Estimates 7
  • High Estimate $-1.22
  • Low Estimate $-2.87
  • Prior Year $-2.78
  • Growth Rate Est. (year over year) +24.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
67.27 +0.67%
on 05/18/26
109.00 -37.87%
on 04/20/26
-17.14 (-20.20%)
since 04/17/26
3-Month
62.50 +8.35%
on 03/09/26
109.00 -37.87%
on 04/20/26
-5.46 (-7.46%)
since 02/18/26
52-Week
7.99 +747.56%
on 06/16/25
109.00 -37.87%
on 04/20/26
+57.44 (+559.08%)
since 05/16/25

Most Recent Stories

More News
Nektar Therapeutics Q1 Earnings Call Highlights

Nektar Therapeutics (NASDAQ:NKTR) outlined plans to advance its lead regulatory T-cell (Treg) therapy rezpegaldesleukin (REZPEG) into late-stage development, while also reporting first-quarter 2026 financial...

NKTR : 67.75 (-4.06%)
Nektar: Q1 Earnings Snapshot

Nektar: Q1 Earnings Snapshot

NKTR : 67.75 (-4.06%)
Nektar Therapeutics Reports First Quarter 2026 Financial Results

SAN FRANCISCO , May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026.

NKTR : 67.75 (-4.06%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTR

NEW YORK , May 7, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. The...

NKTR : 67.75 (-4.06%)
NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options

NKTR : 67.75 (-4.06%)
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Nektar Therapeutics Lawsuit - NKTR

NEW YORK , May 5, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR).

NKTR : 67.75 (-4.06%)
NKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit

NEW YORK , May 4, 2026 /PRNewswire/ -- 

NKTR : 67.75 (-4.06%)
Deadline Soon: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz reminds investors of the upcoming May 5, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on...

NKTR : 67.75 (-4.06%)
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR

LOS ANGELES , May 4, 2026 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations...

NKTR : 67.75 (-4.06%)
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , May 4, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar"...

NKTR : 67.75 (-4.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration...

See More

Key Turning Points

3rd Resistance Point 77.59
2nd Resistance Point 75.70
1st Resistance Point 73.16
Last Price 67.75
1st Support Level 68.73
2nd Support Level 66.84
3rd Support Level 64.30

See More

52-Week High 109.00
Fibonacci 61.8% 70.41
Last Price 67.75
Fibonacci 50% 58.49
Fibonacci 38.2% 46.58
52-Week Low 7.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.